Confirming a Historical Diagnosis of Multiple Sclerosis
Challenges and Recommendations
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received August 12, 2021
- Accepted December 14, 2021
- First Published January 6, 2022.
Article Versions
- Previous version (January 6, 2022 - 13:13).
- You are viewing the most recent version of this article.
Author Disclosures
- Andrew J. Solomon, MD,
- Georgina Arrambide, MD, PhD,
- Wallace Brownlee, MBChB, PhD,
- Anne H. Cross, MD,
- María I. Gaitan, MD,
- Fred D. Lublin, MD,
- Naila Makhani, MD,
- Ellen M. Mowry, MD, MCR,
- Daniel S. Reich, MD, PhD,
- Àlex Rovira, MD,
- Brian G. Weinshenker, MD and
- Jeffrey A. Cohen, MD
- Andrew J. Solomon, MD,
Alexion, Biogen, Celgene, EMD Serono, Genentech Greenwich Biosciences, TG Therapeutics
NONE
NONE
NONE
NONE
NONE
NONE
Biogen, Octave Bioscience
NONE
Compensation for non-promotional speaking from EMD Serono.
NONE
Biogen, Bristol Myers Squibb
NIH/NINDS, K02NS109340 2019-2021 PI
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Georgina Arrambide, MD, PhD,
(1) Sanofi advisory board on alemtuzumab and BTK inhibitors. (2) Merck advisory board on evobrutinib. (3) Roche advisory board on satralizumab.
NONE
(1) Speaking honoraria from Sanofi. (2) Travel and speaking honoraria from Stendhal. (3) Speaking honoraria from Merck. (4) Travel expenses for scientific meetings from Novartis. (5) Travel expenses for scientific meetings from Roche. (6) Travel expenses for scientific meetings from ECTRIMS.
(1) Frontiers in Neurology guest editor for Research Topic: Prognostic and Predictive Factors in Multiple Sclerosis and Related Disorders, 2020-2021 (2) Multiple Sclerosis Journal - Experimental, Translational and Clinical editor for Europe
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Commercial entity: Novartis.
(1) Instituto de Salud Carlos III, ayudas de investigación en salud, FIS number PI19/01590, principal investigator, 2019-2022
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Wallace Brownlee, MBChB, PhD,
Advisory board consulting for Biogen, Celgene, Merck Serono, Mylan, Novartis, Roche and Sanofi
NONE
Speaker honoraria for educational activities for Merck, Roche and Sanofi Genzyme.
Dr Brownlee is case reports editor for Multiple Sclerosis Journal (2018 to present)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Anne H. Cross, MD,
Commercial Entities: (1) Roche: member scientific advisory board 2010-2019 (2)Genentech: member of scientific advisory board 2015-2021; (3) Biogen: consulting; (4) EMD-Serono: consulting and member of scientific advisory board; (5) Horizon: consulting and attendance at advisory board; (6) Novartis: consulting; (7) Celgene: attendance at advisory board; (8) TG Therapeutics: attendance at advisory board; (9) Janssen Biopharmaceuticals: attendance at advisory board; (10) Greenwich Biosciences: attendance at advisory board. Non-Profit: (1) Race to Erase MS (formerly Nancy Davis Center Without Walls): reviewing grants, presence at review meetings; (2) National MS Society: speaking at regional meetings in 2018, 2020; 2021 (3) Consortium of MS Centers: participation in Board of Director meetings, talks at meetings, current Secretary of Board of Governors of CMSC
NONE
(1) gave talk for EMD-Serono in Stockholm 2019, included travel funded by EMD-Serono; (2) spoke at Genentech meetings, included travel (2016 - 2019); (3) research talk at scientific symposium of the Race to Erase MS (Nonprofit). Travel in 2019 was covered, and I received honorarium for talk. Was virtual meeting in 2020 (received honorarium for talk).
(1) 2020- ongoing: Editorial Board member, Neurology: Neuroimmunology & NeuroInflammation - no compensation (2) 2014-ongoing: Advisory Board member, Brain - no compensation; (3) Editorial Board, Journal of Neuroimmunology, Editorial Board, 1996-2020 - no compensation
U.S. patent #15060-630 ÂMethods for simultaneous multi-angular relaxometry of tissue using magnetic resonance imaging
NONE
NONE
(1)Biogen, ad hoc consultant, 2005-2021; (2) Horizon, ad hoc consultant, 2021; (3) Novartis, ad hoc consultant 2013- 2021; (4) Gerson Lehrman Group Austin Tx,consultant 2009-2021, (5) Guidepoint Global, LLC, New York, New York,consultant, ongoing; (6) EMD Serono- ad hoc consultant 2012-2021; (7) TG Therapeutics - ad hoc consultant 2019, 2021; (8) Genentech - ad hoc consultant 2011-2021, (9) Celgene - ad hoc consultant 2018-2020; (10) At Point of Care - writer and commentator on CME programs - 2018,2019, 2020.
I gave two talks in 2019 for the Genentech Speakers' bureau, but have since stepped down from that group.
(1) Projects in Knowledge, Livingston NJ 07039- fee for writing (2) Prime Education, Inc, fee for giving CME talk - 2016 & 2017; (3) honoraria for reviewing grants and serving on Scientific Advisory Board for Race To ERASE MS 2016-2019 (this is also disclosed in Sections above; (4) Catamount LLC Speaking at webinar 5/25/2021; (5) Board of Governors Member, Consortium of MS Centers 2016 ongoing (now Secretary); (6) WebMD, honoraria for filming and speaking on topics related to MS 2016-2019; (7)PeerView CME: talk at symposium at 2018 and 2019 annual meeting of CMSC (8) Academic CME, honoraria for CME talk at ACTRIMS 2018, 2019, 2021; (9)Potomac Ctr for Medical Education - honoraria for giving 5 CME talks in mostly rural areas about MS in 2019; (10) CME Outfitters, LLC, spoke at CME session online, ongoing.
NONE
(1) Roche site PI for study of ocrelizumab in primary progressive MS (ORATORIO- now in open-label extension called OLE), (2) back-up investigator on a study at our site of ocrelizumab for RRMS (OPERA), began in 2011 and are now in open-label extension, (3) Roche - site co-PI of OBOE - open-label study intended to better understand mechanism of action of drug, (4) Site co-PI for CLOCK-MS study funded by EMD-Serono, (5) site PI for CHIMES - open label study of ocrelizumab in minority people with MS (Black, Hispanic/Latino)
(1)National Institutes of Health NINDS 2PO1 NS059560- 01
NONE
(1) Barnes-Jewish Hospital Foundation, PI, 2005-2021 (2) Conrad N Hilton Foundation 2014-2021
NONE
NONE
NONE
NONE
NONE
NONE
- María I. Gaitan, MD,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Fred D. Lublin, MD,
Biogen; EMD Serono; Novartis; Teva; Actelion; Sanofi/Genzyme; Acorda; Roche/Genentech; MedImmune/ Viela Bio; Receptos/Celgene; Medday; Atara Biotherapeutics; Mapi Pharma; Innate Immunotherapeutics; Apitope; Orion Biotechnology; Brainstorm Cell Therapeutics; Jazz Pharmaceuticals; GW Pharma; Mylan; Immunic; Population Council; Avotres; Janssen, BMS; Neurogene; Banner Life Sciences; Labcorp; Entelexo Biotherapeutics; Neuralight
NONE
Most, if not all, consulting activity and scientific boards listed above and below involved travel, all before March 2020, that was either paid for directly or reimbursed.
NONE
NONE
NONE
NONE
Same as Advisory Boards
Sanofi Genzyme- non-promotional EMD Serono- non-promotional
NONE
NONE
Novartis; Biogen; Sanofi, NMSS, NIH; Brainstorm Cell Therapeutics
1) NIH/NINDS- PI, 2018-2021 2) NIH/NINDS- PI, 2018-2021
NONE
1) National Multiple Sclerosis Society- PI, 2014-2019 2) National Multiple Sclerosis Society- PI 2019-2024
NONE
NONE
NONE
Stock Options- Avotres; Neuralight
NONE
I have provided occasional expert testimony in various matters
- Naila Makhani, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NINDS grant number K23NS101099
NONE
Charles H Hood Foundation
NONE
NONE
NONE
NONE
NONE
NONE
- Ellen M. Mowry, MD, MCR,
DSMB member for NIAID
NONE
NONE
NONE
NONE
UptoDate chapter editor
NONE
NONE
NONE
NONE
NONE
(1)Free glatiramer acetate for a clinical trial from Teva Neuroscience. (2)Research funding paid to my institution from Biogen and Genentech (for investigator-initiated studies). (3) Site PI of studies sponsored by Biogen and Genentech
(1)Department of Defense, W81XWH-16-1-0693, 9/2016-9/2021 (2)National Institutes of Health, 1R01NR018851-01A1, 9/2020- 6/2025
NONE
1. National Multiple Sclerosis Society. 2. Patient-Centered Outcomes Research Institute (PCORI)
NONE
NONE
NONE
NONE
NONE
NONE
- Daniel S. Reich, MD, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) Vertex Pharmaceuticals, (2) Sanofi-Genzyme, (3) Abata Therapeutics
National Institute of Neurological Disorders and Stroke, Z01NS003119, 2009-current
NONE
(1) Adelson Medical Research Foundation; (2) National Multiple Sclerosis Society
NONE
NONE
NONE
NONE
NONE
NONE
- Àlex Rovira, MD,
(1) Novartis, (2) Biogen, (3) Genzyme, (4) OLEA Medical, (5) Synthetic MRI, (6) TensorMedical, (7) Roche, (8) Bristol
NONE
(1) Bayer, (2) Teva Pharmaceutical Industries Ltd, (3) Genzyme, (4) Merck-Serono, (5) Biogen Idec, (7) Roche, (8) Novartis
Editorial boards of: (1) Neuroradiology. Editorial board member, 2006 at present; (2) Neurology. Editorial board member, 2021 at present;
NONE
NONE
NONE
NONE
(1) Bayer, (2) Teva Pharmaceutical Industries Ltd, (3) Genzyme, (4) Merck-Serono, (5) Biogen Idec, (6) OLEA Medical, (7) Roche, (8) TMC Academy
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Brian G. Weinshenker, MD and
NONE
NONE
1. Roche, honoraria for participation in symposia regarding neuromyelitis optica, World Congress of Neurology 2019
1. Canadian Journal of Neurological Sciences, editorial board member, 2006-present; no compensation 2. Turkish Journal of Neurology, editorial board member, 2005-present; no compensation
1) NMO-IgG for diagnosis of neuromyelitis optica; application 20050112116; patent issued and technology licensed to R.S.R. Ltd.,Oxford University,MVZ Labor PD Dr. Volkmann und Kollegen GbR, Hospices Civil de Lyon
NONE
NONE
1. Chugai: consulting regarding interpretation of neuromyelitis optica clinical trial 2. Mitsubishi Tanabe: consulting regarding design of neuromyelitis optica clinical trial 3. Roche: consulting regarding design of clinical trial 4. Genentech: consulting regarding design of clinical trial 5. Horizon: consulting and education regarding neuromyelitis optica and role of inebilizumab treatment
NONE
(1)VielaBio Pharmaceuticals, Adjudication Committee Member (2)Alexion Pharmaceuticals, Adjudication Committee Member (3)UCB Biosciences, Adjudication Committee Member
NONE
NONE
NONE
NONE
Guthy Jackson Charitable Foundation, sponsor of research in NMO
NONE
NONE
NMO-IgG for diagnosis of neuromyelitis optica; patent issued and technology licensed to R.S.R. Ltd., Oxford University, MVZ Labor PD Dr. Volkmann und Kollegen GbR and Hospices Civil de Lyon
NONE
NONE
NONE
- Jeffrey A. Cohen, MD
Atara 5/1/20 - consulting Biogen 7/7/21 - consulting Bristol-Myers Squibb 6/26/20 - consulting Convelo 10/30/18 to present - consulting Genentech 5/29/20 - consulting Glaxo Smith Kline 7/23/21 - consulting Janssen 5/19/21 - consulting Mylan 6/17/20 - consulting NervGen 11/16/20 - consulting Novartis 3/8/21 - consulting PSI 11/9/21 - consulting
NONE
H3 Communications 10/14/20 - speaker
2019-present - Editor, Multiple Sclerosis Journal, Sage
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Department of Neurological Sciences (AJS), Larner College of Medicine at the University of Vermont, University Health Center - Arnold 2, Burlington, VT; Servei de Neurologia-Neuroimmunologia (GA), Centre d’Esclerosi Múltiple de Catalunya, (Cemcat), Vall d’Hebron Institut de Recerca, Vall d’Hebron Hospital Universitari, Universitat Autònoma de Barcelona, Barcelona, Spain; National Hospital for Neurology and Neurosurgery (WB), London, United Kingdom; Department of Neurology (AHC), Washington University School of Medicine, St. Louis, MO; Department of Neurology (MIG), Neuroimmunology Section, FLENI, Buenos Aires City, Argentina; The Corinne Goldsmith Dickinson Center for Multiple Sclerosis (FDL), Icahn School of Medicine at Mount Sinai, New York, NY; Departments of Pediatrics and Neurology (NM), Yale School of Medicine, New Haven, CT; Multiple Sclerosis Precision Medicine Center of Excellence (EMM), Johns Hopkins University, Baltimore, MD; Translational Neuroradiology Section (DSR), National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD; Section of Neuroradiology (ÀR), Department of Radiology, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Department of Neurology (BGW), Mayo Clinic, Rochester, MN; and Mellen Center for MS Treatment and Research (JAC), Neurological Institute, Cleveland Clinic, Cleveland, OH.
- Correspondence
Dr. Solomon andrew.solomon{at}uvm.edu
Article usage
Cited By...
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Ann Yeh and Dr. Daniela Castillo Villagrán
► Watch
Related Articles
- No related articles found.